A new report noted that body mass index does not provide a nuanced enough assessment of health as it relates to weight

The way the world defines obesity has been in need of an overhaul, according to some experts, and it could be coming soon thanks to a new set of standards.

New recommendations on how to define obesity would reduce the emphasis on body mass index and take into account health problems from extra weight and other measurements.

A new study finds that three quarters of American adults and half of adolescents are too heavy. That's making more of us sick and creating enormous health care costs.

A front-of-package food label would be a great educational tool. The Trump administration should keep it.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.

For years, medical experts have defined obesity primarily based on body mass index, which measures stored fat by calculating height and weight, to determine a person’s health risks.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.